Advanced Therapy Medicinal Products Market Size & Growth Forecast 2027–2036, By Segments (Therapy Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Advanced Therapy Medicinal Products Market size was more than USD 49.3 billion in 2026 and is set to grow at a 15.2% CAGR between 2027 and 2036, reaching USD 202.94 billion by 2036. The industry revenue for 2027 is estimated at USD 55.61 billion.
Base Year Value (2026)
USD 49.3 billion
CAGR (2027-2036)
15.20%
Forecast Year Value (2036)
USD 202.94 billion
Historical Data Period
2022-2026
Largest Region
North America
Forecast Period
2027-2036
Advanced Therapy Medicinal Products Market Intelligence Snapshot:
-
Regional Market Dynamics:
- North America leads with 47.17% share due to strong biopharmaceutical innovation, advanced clinical development activity, and established manufacturing and regulatory pathways enabling faster commercialization of complex therapies.
- Asia Pacific is expanding at 18.82% CAGR, driven by growing biomanufacturing capacity, rising investment in regenerative medicine, and increasing clinical adoption across advanced healthcare systems.
-
Segment Momentum:
- Tissue Engineered Products lead the market because they address established clinical needs in tissue repair and regeneration, with applications in wound management, orthopedic repair, and reconstructive procedures supporting consistent adoption.
- Gene Therapy is the fastest-growing segment due to increasing focus on treatments that target diseases at the genetic level, particularly for inherited and complex disorders where conventional approaches offer limited benefit.
-
Market Expansion Drivers:
- Increasing commercialization of CAR-T and gene therapies driving breakthrough treatment adoption.
- Rising clinical trials in cell and tissue engineering expanding advanced therapy pipelines.
- Growing CDMO investments enhancing large-scale manufacturing capacity for advanced therapies.
-
Leading Market Participants:
Major companies in the advanced therapy medicinal products market include Novartis AG (Switzerland), Spark Therapeutics, Inc. (USA), Bluebird Bio, Inc. (USA), UniQure N.V. (Netherlands), JCR Pharmaceuticals Co., Ltd. (Japan), Vericel Corporation (USA), Organogenesis Inc. (USA), Kolon TissueGene, Inc. (South Korea), MEDIPOST Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea).
Global Market Forecast Snapshot:
-
Market Outlook:
- 2026 Market Size: USD 49.3 billion
- 2027 Estimated Market Size: USD 55.61 billion.
- Projected Market Size: USD 202.94 billion by 2036
- Growth Forecasts: 15.2% CAGR (2027-2036)
-
Regional and Segment Outlook:
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Tissue Engineered Product (Therapy Type)
- Emerging Opportunity Segment: Gene Therapy (Therapy Type)
Market Growth Drivers and Industry Trends
Increasing commercialization of CAR-T and gene therapies driving breakthrough treatment adoption
Increasing commercialization of CAR-T and gene therapies will drive the advanced therapy medicinal products market growth by expanding access to treatments designed to address complex diseases through targeted cellular and genetic mechanisms. Greater movement from clinical development toward commercial availability supports treatment adoption while encouraging healthcare providers to build capabilities for administering and managing these therapies. The expanding use of personalized therapeutic approaches also strengthens demand for specialized treatment infrastructure, patient monitoring, and supporting services associated with advanced therapies.
Rising clinical trials in cell and tissue engineering expanding advanced therapy pipelines
The advanced therapy medicinal products market growth is being supported by rising clinical activity in cell and tissue engineering, which is broadening the range of therapeutic candidates progressing through development pipelines. Research into engineered cells and tissues can create new approaches for restoring damaged biological functions and addressing conditions where conventional treatments have limitations. As more candidates advance through clinical evaluation, the growing diversity of therapeutic applications increases development activity across specialized advanced therapy areas.
Growing CDMO investments enhancing large-scale manufacturing capacity for advanced therapies
Growing investment by contract development and manufacturing organizations will propel the advanced therapy medicinal products market growth by strengthening specialized production capabilities required for increasingly complex therapies. CDMO capacity can help developers address manufacturing challenges related to process scalability, quality control, specialized facilities, and consistent production while reducing the need to build all capabilities internally. Expanded external manufacturing infrastructure also supports developers as therapies progress from clinical stages toward broader commercial production.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing commercialization of CAR-T and gene therapies driving breakthrough treatment adoption | 2.00% | High | North America, Europe | High | Near Term |
| Rising clinical trials in cell and tissue engineering expanding advanced therapy pipelines | 1.50% | High | North America, Asia Pacific | Medium | Mid Term |
| Growing CDMO investments enhancing large-scale manufacturing capacity for advanced therapies | 1.00% | Moderate | Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Regional Demand Dynamics
Largest Region
North America
47.17% Market Share in 2026
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)
In the advanced therapy medicinal products market, North America accounted for the largest share of 47.17% in 2026, supported by a well-developed biotechnology ecosystem, advanced healthcare infrastructure, and strong clinical research capabilities. The region benefits from established pathways for the development and adoption of innovative therapies, while growing investment in cell and gene-based treatments strengthens demand for advanced manufacturing and specialized therapeutic capabilities. Increasing focus on personalized medicine and the treatment of complex diseases further supports North America's strong market position.
Asia Pacific represents the fastest-growing region, driven by expanding healthcare infrastructure, rising investment in biotechnology, and increasing interest in innovative treatment approaches. Improving research capabilities and greater adoption of advanced medical technologies are creating a more favorable environment for the development and commercialization of next-generation therapies. Growing healthcare needs and efforts to strengthen domestic biopharmaceutical capabilities are also supporting regional expansion.
Key Country Insights
The U.S. continues to prioritize scalable manufacturing, clinical translation, and regulatory coordination for advanced therapy medicinal products. Strong collaboration among biotechnology companies, contract manufacturers, and healthcare providers supports broader adoption of complex cell and gene therapies.
Japan advances the advanced therapy medicinal products market through supportive pathways for regenerative medicine and close integration between academic research and clinical practice. Companies continue investing in specialized manufacturing and patient-focused therapeutic applications.
South Korea is strengthening advanced therapy medicinal products production through expanded biomanufacturing capacity and innovation partnerships. Local developers are focusing on scalable production platforms and internationally aligned quality systems for advanced therapies.
Germany emphasizes high-quality bioprocessing infrastructure and advanced manufacturing standards for advanced therapy medicinal products. The country supports efficient technology transfer between research institutions and commercial production facilities to strengthen product development capabilities.
France supports the advanced therapy medicinal products market by connecting clinical research centers with specialized manufacturing capabilities. Continued investment in translational medicine encourages development of innovative therapies for complex disease areas.
Italy focuses on expanding clinical expertise and specialized manufacturing capabilities for advanced therapy medicinal products. Collaboration between hospitals, research organizations, and biotechnology firms supports wider access to personalized therapeutic solutions.
Segment Leadership and Growth Trends
Therapy Type Segment Analysis: Tissue Engineered Product (Largest Segment) vs Gene Therapy (Fastest-Growing Segment)
Tissue engineered product held the largest share of the advanced therapy medicinal products market in 2026, supported by growing interest in regenerative approaches designed to restore, replace, or repair damaged tissues. Advances in cell-based technologies, biomaterials, tissue engineering, and regenerative medicine are enabling the development of therapies that address conditions where conventional treatment approaches may provide limited restoration of tissue function. Increasing research activity and clinical interest in regenerative solutions are contributing to the established position of tissue engineered products within the advanced therapy landscape.
Gene therapy is expected to be the fastest-growing segment as advances in genetic medicine are expanding opportunities to address diseases at their underlying molecular or genetic causes. Improvements in gene delivery technologies, vector engineering, and therapeutic development are increasing the potential application of gene-based interventions across a broad range of conditions. Rising investment in personalized and potentially disease-modifying treatments, together with continued progress in genetic research, is creating strong momentum for gene therapy adoption.
| Report Segmentation | |||
| Segment | Sub-Segment | Largest Segment | Fastest Growing Segment |
|---|---|---|---|
| Therapy Type | Cell Therapy, Gene Therapy, Tissue Engineered Product | Tissue Engineered Product | Gene Therapy |
Read our Research ApproachCompetitive Landscape and Market Positioning
Top players in the advanced therapy medicinal products market:
1. Novartis AG (Switzerland)
2. Spark Therapeutics Inc. (USA)
3. Bluebird Bio Inc. (USA)
4. UniQure N.V. (Netherlands)
5. JCR Pharmaceuticals Co. Ltd. (Japan)
6. Vericel Corporation (USA)
7. Organogenesis Inc. (USA)
8. Kolon TissueGene Inc. (South Korea)
9. MEDIPOST Co. Ltd. (South Korea)
10. PHARMICELL Co. Ltd. (South Korea)
The advanced therapy medicinal products market is expanding through increased focus on gene therapies, regenerative medicine, and cell-based treatment platforms. Research initiatives targeting rare and complex diseases are encouraging innovation in manufacturing scalability and therapeutic delivery methods. Growing collaboration across biotechnology ecosystems is also accelerating commercialization activities in the advanced therapy medicinal products market.
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| BIH at Charité & ProBioGen | Sep-25 | The Berlin Institute of Health at Charité and ProBioGen established the Berlin Center for Gene and Cell Therapies, featuring a 4,600 m² GMP facility. Supported by €76.5 million in federal funding, this infrastructure project is designed to accelerate the translation of gene and cell therapy research into clinical applications through enhanced manufacturing capacity. |
| Seqens | Apr-24 | Seqens diversified its CDMO service portfolio by acquiring CELLforCURE, marking its formal entry into the cell and gene therapy manufacturing market. This strategic acquisition expands the company’s technical capabilities from small-molecule production into complex ATMP manufacturing, strengthening its competitive positioning within the rapidly evolving biologics and cell-based therapeutic service landscape. |
| UZ Leuven & KU Leuven | Oct-24 | UZ Leuven and KU Leuven invested €14 million to construct a specialized facility for the production of advanced therapy medicinal products at the Gasthuisberg Campus. This investment is intended to bolster regional capacity for developing and manufacturing personalized cell and gene therapies, directly facilitating the clinical translation of novel regenerative medicine treatments. |
| Scinai Immunotherapeutics | May-26 | Scinai Immunotherapeutics acquired Recipharm Israel Ltd. and entered a commercial partnership with Recipharm to augment its capabilities in inflammation and immunology-focused biotherapeutics. This transaction significantly enhances Scinai’s manufacturing and commercialization infrastructure, providing greater operational scale for its participation in the broader cell and gene therapy ecosystem. |
| Recipharm | Oct-25 | Recipharm designated its Germany site as a Centre of Excellence for ATMP manufacturing following a comprehensive facility renovation. This strategic upgrade enhances the company’s capacity for multi-product GMP production, allowing for more robust support of cell and gene therapy development and commercial manufacturing within the European market. |
| Neuland Laboratories | May-26 | Neuland Laboratories partnered with LIR Life Sciences to advance a cell-penetrating peptide platform designed for transdermal GLP-1 delivery. This collaboration integrates novel patch-based peptide delivery technologies into the company's development pipeline, strengthening its technical capabilities in addressing therapeutic delivery challenges within advanced cell and gene therapy modalities. |
| Admaius Capital & Minapharm | Jul-25 | Admaius Capital and Minapharm initiated a strategic partnership to strengthen the African biopharma ecosystem by scaling cell and gene therapy capabilities. The collaboration focuses on enhancing regional biotech innovation, infrastructure, and manufacturing capacity, aimed at improving local access to the development and production of advanced therapy medicinal products. |
| Iran’s Royan Research Institute | Feb-26 | Iran’s Royan Research Institute announced the development of six domestic cell therapy and tissue engineering products, contributing to a national pipeline of approximately 110 advanced therapy medicinal products. This initiative marks a strategic increase in national manufacturing capacity, positioning the institution as a significant developer within the regional regenerative medicine landscape. |
| Porton Advanced | May-26 | Porton Advanced and Dark Horse Consulting Group entered a memorandum of understanding to streamline the clinical translation of cell and gene therapies. The collaboration leverages integrated consulting and CDMO capabilities to optimize investigational new therapy pathways in China, enhancing service delivery for developers seeking to navigate complex ATMP regulatory and development frameworks. |
| BIH at Charité & BioLabs | May-25 | The Berlin Institute of Health at Charité partnered with BioLabs to launch a clinical incubator (CLIC) dedicated to ATMP development. By providing shared infrastructure and specialized support services, the initiative is designed to shorten the transition period for regenerative medicine research, facilitating the progression of clinical-stage therapies toward commercialization. |
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
